Skip to main content
. 2023 May 4;10(1):e001037. doi: 10.1136/bmjgast-2022-001037

Figure 1.

Figure 1

Cumulative incidence of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) by year since onset of inflammatory bowel disease (IBD). Patients were at risk after 1 year of follow-up. Cumulative incidence was calculated directly from Nelson-Aalen cumulative hazard estimates.